Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736418 · ClinicalTrials.gov registry record · Phase 1
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
A Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Abdera Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 12
- Study locations
NCT06736418 is a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung that is actively recruiting participants, run by Abdera Therapeutics. The registered enrollment target is 65 participants, below the 357-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (82% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT06736418, a Phase 1 study of Small Cell Lung Cancer (SCLC) and Large Cell Neuroendocrine Carcinoma of the Lung, is actively recruiting participants, sponsored by Abdera Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 12
- Study locations
Study Summary
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how those doses affect the same types of patients' cancers explored enrolled in Phase 1a.
Conditions Studied
Interventions
- DRUG 225Ac-ABD147
Study Locations (12)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- University of California, San Francisco - San Francisco
- University of California, Los Angeles - Santa Monica
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Sylvester Comprehensive Cancer Center, Univ of Miami - Miami
- Florida Cancer Specialists - Sarasota - Sarasota
Maryland
- United Theranostics - Glen Burnie
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06736418
The ClinicalTrials.gov registry entry for NCT06736418 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 9 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (82% lower). The listed sponsor is Abdera Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 1 intervention - of which 225Ac-ABD147 is the first listed.
NCT06736418 reports 12 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06736418 about?
NCT06736418 is a clinical study titled "Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy". The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based c...
What is the current status of trial NCT06736418?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2025-03-10. Estimated completion is 2027-01.
What conditions does trial NCT06736418 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung.
What interventions are being tested in trial NCT06736418?
The interventions under investigation include: 225Ac-ABD147 (DRUG).
Who is sponsoring clinical trial NCT06736418?
This trial is sponsored by Abdera Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736418 being conducted?
This trial has 12 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Small Cell Lung Cancer (SCLC)
All registered trials for this condition
Large Cell Neuroendocrine Carcinoma of the Lung
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.